Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years

Efavirenz (EFV) is a nonnucleoside reverse transcriptase inhibitor approved worldwide for the treatment of HIV in adults and children over 3 years of age or weighing over 10 kg. Only recently EFV was approved in children over 3 months and weighing at least 3.5 kg in the United States and the Europea...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Man, Chapel, Sunny, Sevinsky, Heather, Savant, Ishani, Cirincione, Brenda, Bertz, Richard, Roy, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879370/
https://www.ncbi.nlm.nih.gov/pubmed/27067333
http://dx.doi.org/10.1128/AAC.02678-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879370/
https://www.ncbi.nlm.nih.gov/pubmed/27067333
http://dx.doi.org/10.1128/AAC.02678-15

Ejemplares similares